ASCO GU Conference Coverage
Filter News By:
Featured News
View all
More News
(PMLiVE.com [UK]) Feb 17, 2020 - Bristol-Myers Squibb has unveiled long-term results for Opdivo in renal cell carcinoma, which demonstrated efficacy with and without CTLA4 blocker Yervoy.
(Medscape Medical News) Feb 14, 2020 - Practice-changing studies in cancer care are almost always the result of an improvement in efficacy that "moves the needle," usually in terms of progression-free or overall survival. But here at...
(Medscape Medical News) Feb 17, 2020 - It seemed like a sensible measure for desperate times, but reducing the standard frequency of doses of bacille Calmette-Guérin (BCG; Merck) for the treatment of high-grade bladder cancer resulted in...
(MedPage Today) Feb 15, 2020 - Patients with cisplatin-ineligible advanced bladder cancer achieved durable objective responses with the combination of pembrolizumab (Keytruda) and a newly approved antibody-drug conjugate (ADC), new data...
(MedPage Today) Feb 17, 2020 - Pairing immunotherapy with stereotactic body radiation therapy (SBRT) produced mixed results in advanced renal cell carcinoma (RCC) in two preliminary trials reported here.
(MedPage Today) Feb 14, 2020 - Immediate treatment of limited metastatic recurrence of prostate cancer led to a fourfold improvement in the proportion of patients alive without androgen deprivation therapy (ADT) at 5 years, according to...
(MedPage Today) Feb 14, 2020 - More than a fourth of men with high-risk prostate cancer had lymph node or distant metastases missed by CT or MRI but detected by PET imaging targeting prostate specific membrane antigen (PSMA), a...
(Yahoo! Finance) Feb 15, 2020 - Mirati Therapeutics, Inc., a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in...
(Decipher) Feb 13, 2020 - Decipher Biosciences today announced that a Decipher GRID molecular subtyping signature, studied in patients from the phase III, randomized controlled trial, CHAARTED, successfully predicted which prostate cancer...
(Dana-Farber) Feb 15, 2020 - Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. Researchers from Dana-Farber Cancer...
Expert Videos

OBR Tweets

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj

Sep 24
Maha Hussain, MD, of @LurieCancer provides perspective on the Phase III PROfound study presented at #ESMO20 https://t.co/NerWJUf67S

Aug 25
At the ASCO20 Virtual Education Program, Nilanjan Ghosh, MD, PhD, a hematologist-oncologist at the @LevineCancer, p… https://t.co/o2s69MGfrW

Aug 25
At the #ASCO20 Virtual Education Program, Jaleh Fallah @Jaleh_Fallah, MD, a Hematology/Oncology Fellow at the Cleve… https://t.co/QDkyebDuvp

Aug 25
The financial toxicity that patients and oncology practices are potentially exposed to due to the high costs associ… https://t.co/QA8A13PAGT

Aug 25
At separate #AACR and #COA virtual meetings held in July, participants discussed the challenges of providing cancer… https://t.co/8fs8SKl65a